Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-10
2007-04-10
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C548S311100, C548S335500
Reexamination Certificate
active
11303665
ABSTRACT:
N-Heterocyclic derivatives of the following formula:where m, n, p, A1, R1, R2, R3and R4are described herein, as well as other N-heterocyclic derivatives, are useful as inhibitors of nitric oxide synthase. Pharmaceutical compositions containing these compounds, methods of using these compounds as inhibitors of nitric oxide synthase and processes for synthesizing these compounds are also described herein.
REFERENCES:
patent: 5051423 (1991-09-01), Lis et al.
patent: 5244865 (1993-09-01), Seitz et al.
patent: 5426110 (1995-06-01), Gossett et al.
patent: 5489591 (1996-02-01), Kobayashi et al.
patent: 5663334 (1997-09-01), Sheldrake et al.
patent: 6057358 (2000-05-01), Chung et al.
patent: 6172005 (2001-01-01), Selby
patent: 6432947 (2002-08-01), Arnaiz et al.
patent: 6525051 (2003-02-01), Davey et al.
patent: 2002/0040024 (2002-04-01), Apodaca et al.
patent: 0 257 850 (1988-03-01), None
patent: 0 306 440 (1989-03-01), None
patent: 0 640 599 (1995-03-01), None
patent: 0 697407 (1995-08-01), None
patent: 0 757 988 (1997-02-01), None
patent: 0 949 242 (1999-10-01), None
patent: WO96/14842 (1996-05-01), None
patent: WO96/14844 (1996-05-01), None
patent: WO98/09960 (1998-03-01), None
patent: WO01/14371 (2001-03-01), None
patent: WO02/32897 (2002-04-01), None
patent: WO03/022821 (2003-03-01), None
Fons et al. Cytokine ((7) 453-462, 1997.
Feldman et al., “The Surprising Life of Nitric Oxide”,Chemical and Engineering News(1993), pp. 26-38.
Del Corona et al., “Synthesis andIn-vitroStudy of Platelet Antiaggregant Activity of 2(4)-imidazol-1-yl-4(2)-cycloalkylaminopyrimidines”,Eur. J. Med. Chem. (1991), vol. 26, No. 7, pp. 729-733.
Fujisawa et al., “Inducible Nitric Oxide Synthase in a Human Glioblastoma Cell Line”,J. Neurochem.(1995) vol. 64, No. 1, pp. 85-91.
Damiani et al., “Fluormetric Determination of Nitrite”Talanta(1986), vol. 33, No. 8, pp. 649-652.
Nathan et al., “Nitric Oxide as a Secretory Product of Mammalian Cells”,FASEB Journal(1992), vol. 6, pp. 3052:3064.
Lampe et al., “A Novel Rearrangement of 1-(2-Aminoaryl)imidazoles”,J. Heterocyclic Chem(1994), vol. 31, pp. 287-291.
Lis et al., “Synthesis of Novel (Aryloxy) propanolamines and Related Compounds Possessing Both Class II and Class III Antiarrhythmic Activity”J. Med. Chem. (1990), vol. 33, pp. 2883-2891.
Ohmori, J. et al., “Novel AMPA Receptor Antagonists: Synthesis and Structure-Activity Relationships of 1-Hydroxy-7-(1-H-imidazol-1-yl)-6-nitro-2,3(1H,4H)-quinoxalinedione and Related Compounds.”J. Chem. Med. (1996), vol. 39, pp. 3971-3979.
Fons A. J. et al., “Effect of Interlukin 1 and Leukaemia Inhibitory Factor on Chondrocyte Metabolism in Articlular Cartilage from Normal and Interleukin-6-Deficient Mice: Role of Nitric Oxide and IL-6 in the Suppression of Proteoglycan Synthesis.”Cytokine. vol. 9, No. 7, pp. 453-462, Jul. 1997.
Davey David
Mohan Raju
Phillips Gary
Wei Guo Ping
Xu Wei
Balasubramanian Venkataraman
Schering Aktiengesellschaft
LandOfFree
N-heterocyclic derivatives as NOS inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-heterocyclic derivatives as NOS inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-heterocyclic derivatives as NOS inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3773835